NEW YORK, September 26, 2016 /PRNewswire/ --
The bioscience technology sector continues to evolve, being a
dynamic field which employs life processes to practical uses, such
as new bioscience procedures and advanced drugs in treating viral
diseases. The large and emerging volume of industry research
indicates future growth within the sector. Companies from across
the field have been investing in cancer research, trying to
reinvent cancer therapy. Spotlight Innovation Inc. (OTCMKTS:
STLT), Immune Pharmaceuticals Inc (NASDAQ: IMNP), NewLink
Genetics Corp. (NASDAQ: NLNK), Merrimack Pharmaceuticals
Inc. (NASDAQ: MACK), Agenus Inc. (NASDAQ: AGEN)
Recently, bioscience company Spotlight Innovation Inc.
(OTC: STLT) has entered into a sponsored research agreement with
Florida State University to battle
against the Zika virus; a virus transmitted by Aedes
mosquitos that currently has no cure or specific treatment.
Spotlight will be supporting FSU professor, Hengli
Tang to create harmless yet effective medicine to treat
patients who are infected with the virus. The company's
innovation focuses on identifying and acquiring rights to
proprietary technologies in areas of unmet medical need,
highlighting on rare or emerging diseases and conditions such as
Zika.
Spotlight Innovation Inc. (STLT) classifies and acquires
rights to innovative, proprietary technologies intended to address
unmet medical needs and focuses importantly on unique, emerging and
neglected diseases. In order to find and assess extraordinary
opportunities, the company strictly leverages their extensive
relationships with well-known scientists, top academic institutions
and other leading sources. This April Spotlight Innovation achieves
key laboratory benchmark for Its Immunoplex™ Immunotherapy Cancer
Vaccine Technology.
Spotlight Innovation Inc. (STLT) earlier in the month
announced that, Cassandra K.
MacArthur has joined the company as Senior Vice President of
Regulatory Affairs and Compliance. Ms. MacArthur will be
responsible for all aspects of regulatory affairs including
strategic planning for regulatory approvals, preparation of
regulatory submissions, serving as the primary contact with the FDA
and other regulatory authorities, and compliance with all
regulatory agencies worldwide.
NewLink Genetics Corporation (NASDAQ: NLNK) is a
biopharmaceutical company focused on discovering, developing and
commercializing immuno-oncology products to improve the lives of
patients suffering from cancer. NewLink's portfolio includes
biologic and small-molecule immunotherapy product candidates for a
range of oncology indications. Its biologic product candidates are
based on its HyperAcute immunotherapy technology platform, which is
designed to stimulate the human immune system and a clinically
advanced product candidate for patients with pancreatic cancer, the
Algenpantucel-L.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is a
clinical-stage biopharmaceutical company engaged in the development
and commercialization of targeted therapeutics in the fields of
immuno-inflammation and immuno-oncology. The Company's
immuno-oncology pipeline includes Ceplene, a small molecule
targeting the Histamine-2 Receptor to overcome immunosuppression in
Acute Myeloid Leukemia and other malignancies. The company's
technology platform, NanomAbs, is a platform that allows the
targeted delivery of chemotherapeutics into cancer cells.
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) has
reported positive sales last quarter of the company's first
commercial product, ONIVYDE, a drug that treats patients with
metastatic pancreatic cancer. The company specified sales increased
by 29% compared to its first quarter, making it at $12.9 million. Merrimack aims to reduce the
uncertainty in drug development and clinical validation, and move
discovery efforts past trial and error. This approach could make
individualized treatment of patients a reality.
Agenus Inc. (NASDAQ: AGEN) has completed enrollment of
the first cohort of patients in its Phase 1 study an anti-CTLA-4
antibody (AGEN1884), which was launched earlier in this
year. Agenus also plans to initiate clinical studies for a
second anti-CTLA-4 antibody, the AGEN2041, in 2017 and thus combine
trials with AGEN1884 during its first half of next year. Agenus is
an immuno-oncology company developing antibodies, including
checkpoint inhibitors and other checkpoint modulators, and cancer
vaccines.
For "The Latest Buzz in Financial News", SIGN UP & Visit:
http://www.FinancialBuzz.com Follow us on Twitter for real time
Financial News Updates: https://twitter.com/financialbuzz Facebook
Like Us to receive live feeds:
https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web
portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth
broadcasts on Stock News, Market Analysis and Company Interviews. A
pioneer in the financially driven digital space, video production
and integration of social media, FinancialBuzz.com creates 100%
unique original content. FinancialBuzz.com also provides financial
news PR branding, marketing and advertising for third parties for
disseminating news and original content through our unique media
platform that includes Newswire Delivery, Digital Advertising,
Social Media Relations, Video Production, Broadcasting, and
Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or
advisor, investment advisor or broker-dealer and do not undertake
any activities that would require such registration. The
information provided on http://www.FinancialBuzz.com (the "Site")
is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content),
FinancialBuzz.com, a financial news media and pr marketing firm
enters into service agreements with the companies which are the
subject to the articles posted on the Site for advertising such
companies. Financialbuzz.com has been compensated twelve thousand dollars for financial news pr
services by a non-affiliated third party for spotlight innovations
inc. We are not an independent news media provider and therefore do
not represent or warrant that the information posted on the Site is
accurate, unbiased or complete. FinancialBuzz.com receives fees for
producing and presenting the high quality and sophisticated content
on this site along with other financial news pr media services. Our
fees may be either a flat cash sum or negotiated number of
securities of the companies featured on this site, or a combination
thereof. The securities are commonly paid in segments, of which a
portion is received upon engagement and the balance is paid on or
near the conclusion of the engagement. FinancialBuzz.com does not
undertake to update any of the information on the Site or continue
to post information about any companies the information contained
herein is not intended to be used as the basis for investment
decisions and should not be considered as investment advice or a
recommendation. The information contained herein is not an offer or
solicitation to buy, hold or sell any security. FinancialBuzz.com,
members and affiliates are not responsible for any gains or losses
that result from the opinions expressed on the Site, company
profiles, quotations or in other materials or presentations that it
publishes electronically or in print. Investors accept full
responsibility for any and all of their investment decisions based
on their own independent research and evaluation of their own
investment goals, risk tolerance, and financial condition.
FinancialBuzz.com. By accessing this website and any pages thereof,
you agree to be bound by the Terms of Use and Privacy Policy, as
may be amended from time to time. None of the content issued by
FinancialBuzz.com constitutes a recommendation for any investor to
purchase, hold or sell any particular security, pursue a particular
investment strategy or that any security is suitable for any
investor. This publication is provided by FinancialBuzz.com. Each
investor is solely responsible for determining whether a particular
security or investment strategy is suitable based on their
objectives, other securities holdings, financial situation needs,
and tax status. You agree to consult with your investment advisor,
tax and legal consultant before making any investment decisions. We
make no representations as to the completeness, accuracy or
timeless of the material provided. All materials are subject to
change without notice. Information is obtained from sources
believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use.
Please visit: http://www.financialbuzz.com
For further information:
Media Contact: Danny A, info@financialbuzz.com ,
+1-877-601-1879
SOURCE FinancialBuzz.com